Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study

This publication has 15 references indexed in Scilit:

• Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
  Journal of Crohn's and Colitis, 2021
• Comparing cost of intravenous infusion and subcutaneous biologics in COVID‐19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: A brief UK stakeholder survey
  International Journal Of Clinical Practice, 2021
• Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
  Gastroenterology, 2020
• Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
  Clinical Gastroenterology and Hepatology, 2018
• Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
  BioDrugs, 2018
• Ulcerative colitis
  The Lancet, 2017
• Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting
  Journal of Medical Economics, 2017
• An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
  Journal of Crohn's and Colitis, 2016
• How do patients with inflammatory bowel disease want their biological therapy administered?
  BMC Gastroenterology, 2010
• Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
  New England Journal of Medicine, 1987